But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
The group looks like the gene therapy contender to beat, but that is not saying much.
Spac backtrack confirms that the gene therapy bubble has burst
The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?
But a serious adverse event and waning enzyme levels raise questions about the data.
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.